Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 3, 2009, Pages 301-306

  Fass, R ^a   Pieniaszek, H J ^b   Thompson, J R ^c,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b HPP Consulting and Services Inc   (United States)

^c LIPSCOMB UNIVERSITY   (United States)

^d LIPSCOMB UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METOCLOPRAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TABLET;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DEGLUTITION DISORDERS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MEDICATION ADHERENCE; METOCLOPRAMIDE; MIDDLE AGED; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 67650450511     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04045.x     Document Type: Article

References (19)

1. Fasano A. Novel approaches for oral delivery of macromolecules. J Pharm Sci 1998 87 : 1351 6.
2. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery - a review. Pharm Sci Technolo Today 2000 3 : 138 45.
3. van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther 2003 25 : 1687 99.
4. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992 136 : 165 77.
5. Kawashima K, Motohashi Y, Fujishima I. Prevalence of dysphagia among community-dwelling elderly individuals as estimated using a questionnaire for dysphagia screening. Dysphagia 2004 19 : 266 71.
6. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998 50 : 375 82.
7. Haans JJ, Masclee AA. Review article: the diagnosis and management of gastroparesis. Aliment Pharmacol Ther 2007 26 (Suppl 2 37 46. (Pubitemid 350233342)
8. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006 3 : 138 48.
9. Reglan [package insert]. Milwaukee, WI : Schwarz Pharma, Inc, 2004.
10. Flockhart D. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine 2007. http://medicine.iupui.edu/flockhart/ table.htm. Accessed December 9, 2008.
11. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983 98 : 86 95. (Pubitemid 13217970)
12. Camilleri M. Diabetic gastroparesis. N Engl J Med 2007 356 : 820 9.
13. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983 6 : 463 7.
14. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999 94 : 1230 4.
15. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 2004 12 : 432 40.
16. Brodie J. Fact sheet 47: diabetes in practice: gastroparesis. http://www.diabetes.org.uk/Documents/Update/2007/Winter/factsheet47.pdf. Accessed October 20, 2008.
17. De Block CE, De Leeuw IH, Pelckmans PA, Van Gaal LF. Current concepts in gastric motility in diabetes mellitus. Curr Diabetes Rev 2006 2 : 113 30.
18. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998 11 : 252 9.
19. Van Vleet TR, Bombick DW, Coulombe RA Jr. Inhibition of human cytochrome P450 2E1 by nicotine, cotinine, and aqueous cigarette tar extract in vitro. Toxicol Sci 2001 64 : 185 91.